On the stock market since 2013, it operates in the world of health and science. It has 6 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 87% a year over the last 4 years. Red columns mark years that ended in a loss.
If every debt were paid off today, $3.8M would still be left in the vault — a solid cushion for hard times.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Bets Against the Stock: The number of investors betting on a fall stands out.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 329% — that slice of every sale is the company’s cushion in hard quarters.
Over the last 3 years, sales grew about 131% a year on average.
There is $3.8M in the vault; even if every debt were paid off, $3.8M would remain.
The stock sits at $0.76. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
The weight of investors positioned for a fall can be felt in the market. Council score: 4/10.
On our five-subject report card, TRAW sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: TRAW is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.